Effects of fenofibrate on lipid parameters in obese rhesus monkeys

Deborah A. Winegar, Peter J. Brown, William O. Wilkison, Michael C. Lewis, Ronda J. Ott, W. Q. Tong, H. Roger Brown, Jurgen M. Lehmann, Steven A. Kliewer, Kelli D. Plunket, James M. Way, Noni L. Bodkin, Barbara C. Hansen

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Fenofibrate is a member of the fibrate class of hypolipidemic agents used clinically to treat hypertriglyceridemia and mixed hyperlipidemia. The fibrates were developed primarily on the basis of their cholesterol and triglyceride lowering in rodents. Fibrates have historically been ineffective at lowering triglycerides in experimentally-induced dyslipidemia in nonhuman primate models. The spontaneously obese rhesus monkey is a well-recognized animal model for the study of human obesity and type 2 diabetes, and many of these monkeys exhibit naturally occurring lipid abnormalities, including elevated triglycerides and low HDL cholesterol (HDL-C), similar to patients with type 2 diabetes. To explore whether the obese rhesus model was predictive of the lipid lowering effects of fibrates, we evaluated fenofibrate in six hypertriglyceridemic, hyperinsulinemic, non-diabetic animals in a 20-week, dose-escalating study. The study consisted of a 4-week baseline period, two treatment periods of 10 mg/kg twice daily (b.i.d) for 4 weeks and 30 mg/kg b.i.d. for 8 weeks, and a 4-week washout period. Fenofibrate (30 mg/kg b.i.d) decreased serum triglycerides 55% and LDL-C 27%, whereas HDL-C increased 35%. Apolipoproteins B-100 and C-III levels were also reduced 70% and 29%, respectively. Food intake, body weight, and plasma glucose were not affected throughout the study. Interestingly, plasma insulin levels decreased 40% during the 30 mg/kg treatment period, suggesting improvement in insulin sensitivity. These results support the use of obese rhesus monkey as an excellent animal model for studying the effects of novel hypolipidemic agents, particularly agents that impact serum triglycerides and HDL-C.

Original languageEnglish (US)
Pages (from-to)1543-1551
Number of pages9
JournalJournal of Lipid Research
Volume42
Issue number10
StatePublished - 2001

Fingerprint

Fenofibrate
Fibric Acids
Macaca mulatta
Triglycerides
Lipids
Hypolipidemic Agents
Animals
Type 2 Diabetes Mellitus
HDL Cholesterol
Medical problems
Animal Models
Apolipoproteins C
Apolipoprotein B-100
Hypertriglyceridemia
Insulin
Plasmas
Dyslipidemias
Hyperlipidemias
Serum
Primates

Keywords

  • Apolipoprotein C-III
  • Fibrate
  • HDL-C
  • PPARα
  • Triglyceride-lowering

ASJC Scopus subject areas

  • Endocrinology

Cite this

Winegar, D. A., Brown, P. J., Wilkison, W. O., Lewis, M. C., Ott, R. J., Tong, W. Q., ... Hansen, B. C. (2001). Effects of fenofibrate on lipid parameters in obese rhesus monkeys. Journal of Lipid Research, 42(10), 1543-1551.

Effects of fenofibrate on lipid parameters in obese rhesus monkeys. / Winegar, Deborah A.; Brown, Peter J.; Wilkison, William O.; Lewis, Michael C.; Ott, Ronda J.; Tong, W. Q.; Brown, H. Roger; Lehmann, Jurgen M.; Kliewer, Steven A.; Plunket, Kelli D.; Way, James M.; Bodkin, Noni L.; Hansen, Barbara C.

In: Journal of Lipid Research, Vol. 42, No. 10, 2001, p. 1543-1551.

Research output: Contribution to journalArticle

Winegar, DA, Brown, PJ, Wilkison, WO, Lewis, MC, Ott, RJ, Tong, WQ, Brown, HR, Lehmann, JM, Kliewer, SA, Plunket, KD, Way, JM, Bodkin, NL & Hansen, BC 2001, 'Effects of fenofibrate on lipid parameters in obese rhesus monkeys', Journal of Lipid Research, vol. 42, no. 10, pp. 1543-1551.
Winegar DA, Brown PJ, Wilkison WO, Lewis MC, Ott RJ, Tong WQ et al. Effects of fenofibrate on lipid parameters in obese rhesus monkeys. Journal of Lipid Research. 2001;42(10):1543-1551.
Winegar, Deborah A. ; Brown, Peter J. ; Wilkison, William O. ; Lewis, Michael C. ; Ott, Ronda J. ; Tong, W. Q. ; Brown, H. Roger ; Lehmann, Jurgen M. ; Kliewer, Steven A. ; Plunket, Kelli D. ; Way, James M. ; Bodkin, Noni L. ; Hansen, Barbara C. / Effects of fenofibrate on lipid parameters in obese rhesus monkeys. In: Journal of Lipid Research. 2001 ; Vol. 42, No. 10. pp. 1543-1551.
@article{215f3662532144169fb272d45f3b8d74,
title = "Effects of fenofibrate on lipid parameters in obese rhesus monkeys",
abstract = "Fenofibrate is a member of the fibrate class of hypolipidemic agents used clinically to treat hypertriglyceridemia and mixed hyperlipidemia. The fibrates were developed primarily on the basis of their cholesterol and triglyceride lowering in rodents. Fibrates have historically been ineffective at lowering triglycerides in experimentally-induced dyslipidemia in nonhuman primate models. The spontaneously obese rhesus monkey is a well-recognized animal model for the study of human obesity and type 2 diabetes, and many of these monkeys exhibit naturally occurring lipid abnormalities, including elevated triglycerides and low HDL cholesterol (HDL-C), similar to patients with type 2 diabetes. To explore whether the obese rhesus model was predictive of the lipid lowering effects of fibrates, we evaluated fenofibrate in six hypertriglyceridemic, hyperinsulinemic, non-diabetic animals in a 20-week, dose-escalating study. The study consisted of a 4-week baseline period, two treatment periods of 10 mg/kg twice daily (b.i.d) for 4 weeks and 30 mg/kg b.i.d. for 8 weeks, and a 4-week washout period. Fenofibrate (30 mg/kg b.i.d) decreased serum triglycerides 55{\%} and LDL-C 27{\%}, whereas HDL-C increased 35{\%}. Apolipoproteins B-100 and C-III levels were also reduced 70{\%} and 29{\%}, respectively. Food intake, body weight, and plasma glucose were not affected throughout the study. Interestingly, plasma insulin levels decreased 40{\%} during the 30 mg/kg treatment period, suggesting improvement in insulin sensitivity. These results support the use of obese rhesus monkey as an excellent animal model for studying the effects of novel hypolipidemic agents, particularly agents that impact serum triglycerides and HDL-C.",
keywords = "Apolipoprotein C-III, Fibrate, HDL-C, PPARα, Triglyceride-lowering",
author = "Winegar, {Deborah A.} and Brown, {Peter J.} and Wilkison, {William O.} and Lewis, {Michael C.} and Ott, {Ronda J.} and Tong, {W. Q.} and Brown, {H. Roger} and Lehmann, {Jurgen M.} and Kliewer, {Steven A.} and Plunket, {Kelli D.} and Way, {James M.} and Bodkin, {Noni L.} and Hansen, {Barbara C.}",
year = "2001",
language = "English (US)",
volume = "42",
pages = "1543--1551",
journal = "Journal of Lipid Research",
issn = "0022-2275",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "10",

}

TY - JOUR

T1 - Effects of fenofibrate on lipid parameters in obese rhesus monkeys

AU - Winegar, Deborah A.

AU - Brown, Peter J.

AU - Wilkison, William O.

AU - Lewis, Michael C.

AU - Ott, Ronda J.

AU - Tong, W. Q.

AU - Brown, H. Roger

AU - Lehmann, Jurgen M.

AU - Kliewer, Steven A.

AU - Plunket, Kelli D.

AU - Way, James M.

AU - Bodkin, Noni L.

AU - Hansen, Barbara C.

PY - 2001

Y1 - 2001

N2 - Fenofibrate is a member of the fibrate class of hypolipidemic agents used clinically to treat hypertriglyceridemia and mixed hyperlipidemia. The fibrates were developed primarily on the basis of their cholesterol and triglyceride lowering in rodents. Fibrates have historically been ineffective at lowering triglycerides in experimentally-induced dyslipidemia in nonhuman primate models. The spontaneously obese rhesus monkey is a well-recognized animal model for the study of human obesity and type 2 diabetes, and many of these monkeys exhibit naturally occurring lipid abnormalities, including elevated triglycerides and low HDL cholesterol (HDL-C), similar to patients with type 2 diabetes. To explore whether the obese rhesus model was predictive of the lipid lowering effects of fibrates, we evaluated fenofibrate in six hypertriglyceridemic, hyperinsulinemic, non-diabetic animals in a 20-week, dose-escalating study. The study consisted of a 4-week baseline period, two treatment periods of 10 mg/kg twice daily (b.i.d) for 4 weeks and 30 mg/kg b.i.d. for 8 weeks, and a 4-week washout period. Fenofibrate (30 mg/kg b.i.d) decreased serum triglycerides 55% and LDL-C 27%, whereas HDL-C increased 35%. Apolipoproteins B-100 and C-III levels were also reduced 70% and 29%, respectively. Food intake, body weight, and plasma glucose were not affected throughout the study. Interestingly, plasma insulin levels decreased 40% during the 30 mg/kg treatment period, suggesting improvement in insulin sensitivity. These results support the use of obese rhesus monkey as an excellent animal model for studying the effects of novel hypolipidemic agents, particularly agents that impact serum triglycerides and HDL-C.

AB - Fenofibrate is a member of the fibrate class of hypolipidemic agents used clinically to treat hypertriglyceridemia and mixed hyperlipidemia. The fibrates were developed primarily on the basis of their cholesterol and triglyceride lowering in rodents. Fibrates have historically been ineffective at lowering triglycerides in experimentally-induced dyslipidemia in nonhuman primate models. The spontaneously obese rhesus monkey is a well-recognized animal model for the study of human obesity and type 2 diabetes, and many of these monkeys exhibit naturally occurring lipid abnormalities, including elevated triglycerides and low HDL cholesterol (HDL-C), similar to patients with type 2 diabetes. To explore whether the obese rhesus model was predictive of the lipid lowering effects of fibrates, we evaluated fenofibrate in six hypertriglyceridemic, hyperinsulinemic, non-diabetic animals in a 20-week, dose-escalating study. The study consisted of a 4-week baseline period, two treatment periods of 10 mg/kg twice daily (b.i.d) for 4 weeks and 30 mg/kg b.i.d. for 8 weeks, and a 4-week washout period. Fenofibrate (30 mg/kg b.i.d) decreased serum triglycerides 55% and LDL-C 27%, whereas HDL-C increased 35%. Apolipoproteins B-100 and C-III levels were also reduced 70% and 29%, respectively. Food intake, body weight, and plasma glucose were not affected throughout the study. Interestingly, plasma insulin levels decreased 40% during the 30 mg/kg treatment period, suggesting improvement in insulin sensitivity. These results support the use of obese rhesus monkey as an excellent animal model for studying the effects of novel hypolipidemic agents, particularly agents that impact serum triglycerides and HDL-C.

KW - Apolipoprotein C-III

KW - Fibrate

KW - HDL-C

KW - PPARα

KW - Triglyceride-lowering

UR - http://www.scopus.com/inward/record.url?scp=0034753632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034753632&partnerID=8YFLogxK

M3 - Article

VL - 42

SP - 1543

EP - 1551

JO - Journal of Lipid Research

JF - Journal of Lipid Research

SN - 0022-2275

IS - 10

ER -